We propose that removal of DMD exon 5 alone is unlikely to provide significant clinical benefit, and alternative exon skipping strategies or treatments should be considered for dystrophinopathy patients with mutations within exon 5, or those with duplications of exon 5. Here, DMD is linked to neuromuscular disease caused by qualitative or quantitative defects of dystrophin.